Literature DB >> 16096742

[New concept minimizes bleeding in radical retropubic prostatectomy].

M Schostak1, K Matischak, M Schäfer, M Müller, M Schrader, F Christoph, K Miller.   

Abstract

BACKGROUND: Radical retropubic prostatectomy is an intervention known to be associated with severe bleeding. Even experienced surgeons report a blood transfusion rate of up to 20%. The perioperative concept for this intervention underwent various modifications in January 2001. This study describes the effect of these modifications on the blood loss in a retrospective analysis comparing approximately 100 operations by a single experienced surgeon before the change (group 1) with 100 operations thereafter (group 2).
MATERIALS AND METHODS: The new perioperative concept comprised the following points: reducing the intravenously applied volume, employing a peridural catheter (PDC), and maintaining a 25-30 degrees Trendelenburg's position. The difference in pre- and postsurgical hemoglobin (Hb) was analyzed before (group 1) and after the intervention (group 2). If transfusions were performed, this value was corrected according to the following formula: 1 ml of erythrocyte concentrate increases the patient's Hb by 0.003 g/dl.
RESULTS: Assessment was possible in 201 of 234 cases, 110 from the first and 91 from the second group. The mean transfusion-corrected Hb difference was 5.3 g/dl in group 1 (20% transfusion rate) and 3.52 g/dl in group 2 (1.09% transfusion rate); p>0.0001. The median intravenous volume applied was 5.960 ml in group 1 and 3.490 ml in group 2 (p>0.0001). The complication rate did not differ between groups.
CONCLUSION: The new perioperative concept minimizes the intraoperative blood loss during radical open retropubic prostatectomy. Transfusions are only necessary in rare cases. The complication rate remains unaltered.

Entities:  

Mesh:

Year:  2005        PMID: 16096742     DOI: 10.1007/s00120-005-0888-3

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  26 in total

1.  Recombinant activated factor VII and perioperative blood loss.

Authors:  David Williams; Robert McCarthy
Journal:  Lancet       Date:  2003-05-17       Impact factor: 79.321

2.  Transperitoneal or extraperitoneal approach for laparoscopic radical prostatectomy: a false debate over a real challenge.

Authors:  X Cathelineau; D Cahill; H Widmer; F Rozet; H Baumert; G Vallancien
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

3.  Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial.

Authors:  Philip W Friederich; Christiaan P Henny; Embert J Messelink; Mark G Geerdink; Tymen Keller; Karl-Heinz Kurth; Harry R Büller; Marcel Levi
Journal:  Lancet       Date:  2003-01-18       Impact factor: 79.321

4.  [The significance of comorbidity and age in radical prostatectomy].

Authors:  M Wirth; M Fröhner
Journal:  Urologe A       Date:  2004-08       Impact factor: 0.639

5.  [The effect of ischemic and cardioplegic heart standstill on the myocard metabolism in normal and less perfused heart (author's transl)].

Authors:  O Elert; F Tschirkov; P Satter
Journal:  Thoraxchir Vask Chir       Date:  1975-06

6.  Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies.

Authors:  W J Catalona; G F Carvalhal; D E Mager; D S Smith
Journal:  J Urol       Date:  1999-08       Impact factor: 7.450

7.  Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003.

Authors:  Masood A Khan; Misop Han; Alan W Partin; Jonathan I Epstein; Patrick C Walsh
Journal:  Urology       Date:  2003-07       Impact factor: 2.649

8.  Complications from treatment for prostate carcinoma among men in the Detroit area.

Authors:  Kendra Schwartz; Scott Bunner; Ryan Bearer; Richard K Severson
Journal:  Cancer       Date:  2002-07-01       Impact factor: 6.860

9.  Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.

Authors:  H Zincke; J E Oesterling; M L Blute; E J Bergstralh; R P Myers; D M Barrett
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

Review 10.  Noradrenaline and the kidney: friends or foes?

Authors:  R Bellomo; D D Giantomasso
Journal:  Crit Care       Date:  2001-10-22       Impact factor: 9.097

View more
  1 in total

1.  Hemodynamic effects of orally administered delta-ALA during radical prostatectomy.

Authors:  Volker Eichhorn; Alexander Maerz; Georg Salomon; Irmgard F Blanc; Daniel A Reuter; Alwin E Goetz
Journal:  World J Urol       Date:  2011-11-26       Impact factor: 4.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.